Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

By H. Büller, H. Décousus, M. Grosso, M. Mercuri, S. Middeldorp, M. Prins, G. Raskob, S. Schellong, L. Schwocho, A. Segers and 3 more. New England Journal of Medicine, 2013

1,829 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Hematology, Internal Medicine

View Paper: https://www.semanticscholar.org/paper/cad6273c60eeb98c31dd6e428fcd37a90fe54c70

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Jeroen J. Bax
2. S. Schulman
3. Jose Luis Zamorano
4. P. Lancellotti
5. G. Agnelli

In Hematology

1. S. Konstantinides

In Internal Medicine

1. G. Agnelli
2. S. Konstantinides
3. H. Büller

Citations in the corpus

• ESC Guidelines on the diagnosis and management of acute pulmonary embolism (2014, methodology): “The HokusaI–VTE study compared the direct factor Xa inhibitor edoxaban with conventional therapy in 8240 patients with acute VTE (3319 of whom presented with PE) who had initially received heparin for at least 5 days (Table 11).(298) Patients received edoxaban at a dose of 60 mg once daily (reduced ”
• Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. (2014, methodology): “For Hokusai-VTE, we used event data for the overall study period.(3) The group of patients with impaired renal function includes 28 DOAC recipients and 32 VKA recipients with a creatinine clearance ,30 mL per minute (protocol violations).”
• [2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. (2014, neutral): “The HokusaI–VTE study compared the direct factor Xa inhibitor edoxaban with conventional therapy in 8240 patients with acute VTE (3319 of whom presented with PE) who had initially received heparin for at least 5 days (Table 11).(298) Patients received edoxaban at a dose of 60 mg once daily (reduced ”
• 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) (2019, background): “If dabigatran or edoxaban is chosen for extended anticoagulation after PE, the dose should remain unchanged, as reduced-dose regimens were not investigated in dedicated extension trials.(313,350) Especially for patients receiving NOACs.”